AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01643447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
Study NCT01643447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diammonium glycyrrhizinate
Study NCT03936153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abexinostat
Description: abexinostat tablet
Study NCT03638960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either liposomal bupivacaine prior to the patient receiving surgery.
Study NCT03638960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either plain bupivacaine prior to the patient receiving surgery.
Study NCT00910845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
Study NCT00910845 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
Study NCT00910845 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: normal saline
Description: Normal saline (placebo) injected into the detrusor at Day 1.
Study NCT06478329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Core Stabilization Exercise Training
Description: The effects of 6 weeks progressive core stabilization exercise training on adolescent volleyball players' balance, strength and endurance
Study NCT01590901 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Probucol
Description: 250mg (1 tablet) bid. p.o for 14 consecutive days
Study NCT03948152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the sites standard of care.
Study NCT03948152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mask Advice Tool
Description: Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the mask advice tool.
Study NCT02191345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Guided imagery is a stress management technique that uses verbal suggestion and descriptive language to guide the listener into imagining sensations and visualizing images in the mind in order to bring about a desired physical response, such as reduction in anxiety, stress, or pain. The guided imagery tracks chosen for the study were chosen because their goal is relaxation and stress relief, and their length is under 15 minutes.
Study NCT00512499 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered
Study NCT00512499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention
Description: Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
Study NCT00512499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Intervention
Description: INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.~Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)
Study NCT01383018 — intervention group
Intervention type: DEVICE
Intervention: AMS Penile Prosthesis Devices
Description: Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
Study NCT02646319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02646319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle Albumin-Bound Rapamycin
Description: Given IV
Study NCT02646319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02488018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Provision of experimental honey
Description: Acacia, Becium grandiflorum, Croton macrostachys, Eucalyptus globules, Hypoestes, Leaucas abyssinica, Schefflera abyssinica, Syzygium guineense and reference glucose were used as test food.~25g available carbohydrate of the test food was provided to ten human subjects after fasted for 11 hours overnight.
Study NCT02574364 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: The application of abdomen CT
Description: A modified incision(MI)was designed based on abdomen CT.Using a MI compare traditional incision(TI) to the patient including cut extended, operating time,cut infection, false-positive rate,rehabilitation and return to work.
Study NCT02574364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional incision
Description: McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
Study NCT03871985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subglottic secretion lavage combined with aspiration
Description: Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion lavage combined with aspiration was performed every 4 hours: Underwent preoxygenation before cuff pressure checking, and was maintained between 30 and 35 cmH2O. After aspirating secretions from the mouth, nose, and airway, 2-5 mL distilled sterile water was instilled through the subglottic lumen, and then the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat lavage and aspiration until the irrigation fluid is clear. After washing, cuff pressure checking and was maintained between 25 and 30 cmH2O.
Study NCT03871985 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subglottic secretion aspiration
Description: Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion aspiration was performed every 4 hours:Underwent preoxygenation before cuff pressure checking ,and was maintained between 25 and 30 cmH2O. After aspirating secretions from the mouth, nose, and airway, the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat suction until the secretion is completely absorbed.
Study NCT02537665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: heating precondition
Study NCT02537665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: heating precondition
Study NCT01148264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 1x10mg per day for three days
Study NCT01148264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: 3x10mg per day for three days
Study NCT01151969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New multicomponent 7H intervention
Description: The GPs in the intervention group will undertake an interactive workshop training session (15 hours) on the '7 hypotheses' (7H) intervention. In short, this intervention encourages GPs to select from a list of seven possible hypotheses for why the patient is a frequent attender: biological, psychological, social, family, cultural, administrative-organisational, or related to the doctor-patient relationship.
Study NCT02853045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: period with drug (trade name) then period with generic
Description: The list of drugs is detailed in the study description
Study NCT02853045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: period with generic then period with drug (trade name)
Description: The list of drugs is detailed in the study description
Study NCT00436826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Participants were administered with cladribine tablets orally as cumulative dose.
Study NCT00436826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cladribine
Description: Participants were administered with cladribine tablets orally as cumulative dose.
Study NCT00436826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were administered with placebo orally.
Study NCT00436826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta)
Description: Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
Study NCT00436826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta (IFN-beta)
Description: Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
Study NCT00822146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT
Description: classified
Study NCT02423083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanabenz
Study NCT01358786 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: quilting suture
Description: * quilting sutures and drains~* quilting sutures but no drains
Study NCT01358786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quilting suture
Description: * quilting sutures and drains~* quilting sutures but no drains
Study NCT04577417 — intervention group
Intervention type: DRUG
Intervention: ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Description: Both ADHD and control groups of subjects will participate in 2 sessions (on-med and off-med conditions) conducted on the same day. ADHD group will be asked to come to the laboratory in the morning before taking their morning ADHD stimulant medication. They will be tested before and after taking their ADHD medication (off-med and on-med conditions). The investigators will observe changes between the two conditions.
Study NCT02195973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
Study NCT04224532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum Timing (Before Positioning)
Description: Before Reverse Trendelenburg Position
Study NCT04224532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum Timing (After Positioning)
Description: After Reverse Trendelenburg Position
Study NCT03480594 — intervention group
Intervention type: DRUG
Intervention: MRI Tracer
Description: Hyperpolarized \[1-13C\] pyruvate for injection under IND133229 used to enhance MRI/MRS/MRSI using a 3T MRI scanner.
Study NCT01539746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVI without BAV
Description: Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
Study NCT01539746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAVI standard procedure
Description: TAVI standard procedure including BAV before valve deployment
Study NCT01765569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
Study NCT01765569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
Study NCT00650338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 ophthalmic solution, low concentration
Description: Topical ocular application
Study NCT00650338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 ophthalmic solution, medium concentration
Description: Topical ocular application
Study NCT00650338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 ophthalmic solution, high concentration
Description: Topical ocular application
Study NCT00650338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00650338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.005% latanoprost
Description: Topical ocular application
Study NCT02981914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.
Study NCT02401035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV pantoprazole
Description: Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight
Study NCT02998996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg HA/strain and 1% Endocine™
Description: intranasal administration
Study NCT02998996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg HA/strain and 2% Endocine™
Description: intranasal administration
Study NCT02998996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg HA/strain
Description: intranasal administration
Study NCT02998996 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intramuscular comparator
Description: intramuscular administration
Study NCT02998996 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intranasal comparator
Description: intranasal administration
Study NCT02998996 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Saline
Description: intranasal administration
Study NCT02447913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher
Description: Introduction of vouchers will improve uptake of family method as well as child immunization.~Incentivizing the providers to improve their counseling skills will improve the provider client relationship and better compliance of Family planning method
Study NCT04333212 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DR. Chip HPV genotyping IVD kit
Description: HPV typing by gene chip
Study NCT00921713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncology Nurse Care Management
Study NCT00921713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-centered materials
Study NCT04326387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SAMBA II (Diagnostic for the Real World)
Description: Point of care Isothermal-PCR Viral RNA Amplication for virus detection
Study NCT04326387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Public Health England Gold Standard
Description: Reverse Transcription PCR
Study NCT04326387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cambridge Validated Viral Detection Method
Description: Reverse Transcription PCR
Study NCT04326387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological Detection
Description: Chest X-ray \& CT Scan detection of viral infection in the lungs
Study NCT03731390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR1405 injection
Description: Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.
Study NCT04685642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (100mg/day)
Study NCT04685642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin (20mg/day)
Study NCT02169843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: inhale Sevoflurane
Study NCT02169843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: inhale Sevoflurane
Study NCT02169843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intravenous pumping Dexmedetomidine 0.2µg/kg/h
Study NCT02169843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Dexmedetomidine)
Description: normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
Study NCT01916460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)
Description: After the subjects meet the criteria for enrollment in the study, gastroparetic patients will undergo linear EUS examination of the stomach wall one day prior to their surgery to obtain single or multiple core biopsies of the stomach body wall using the 19-gauge core biopsy needle under EUS guidance. The pathologist will be in the room to assess the adequacy of the sample after each pass. Once the pathologist deemed that the obtained sample is sufficient, the procedure will be terminated
Study NCT01871077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-156
Description: Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
Study NCT02716584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Veterans in the physical exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups, held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age).
Study NCT02716584 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: Veterans in the control condition will participate in instructor-led, non-aerobic stretching exercises conducted in small groups, held 3 times per week.
Study NCT00585338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem 532/1064 nm Laser
Description: Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
Study NCT02787122 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-E
Description: Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy based on a manual. Interventions aim on patients' mood by implementing positive activities in their daily routine. Further, patients train to reduce worrying behavior. Social contacts are fostered as well. Later, patients are informed on emotions and train emotion regulation strategies. Finally, the focus of CBT-E is on self-acceptance.Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
Study NCT02787122 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Patients receive standardized treatment. After a waiting period of six month, patients receive CBT-E
Study NCT06361186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proximod
Description: Single and multiple-dose to establish the safety and PK profile
Study NCT06361186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo controlled
Study NCT02951624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control intervention
Study NCT02951624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaker
Description: Short breaks of physical activity